Date of Original Version
Ponatinib (Iclusig; Ariad Pharmaceuticals) is an oral tyrosine kinase inhibitor (TKI) that was approved by FDA on December 14, 2012, for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myelogenous leukemia (CML) that is resistant or intolerant to previous TKI therapy, and for Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (Ph+ALL).
Brett Feret. (2013). Ponatinib: An oral tyrosine kinase inhibitor for the treatment of CML and Ph+ALL. Formulary, 169+. Retrieved from http://www.formularywatch.com/feature-articles/ponatinib-oral-tyrosine-kinase-inhibitor-treatment-chronic-myelogenous-leukemia-and-philadelphia